Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-C: Simplified Monitoring for Glecaprevir/Pibrentasvir in Chronic HCV
NCT03117569Phase 3Completed
- Sponsor
- The Kirby Institute
- Start
- Aug 2017
- Primary completion
- Dec 2018
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of glecaprevir and pibrentasvir in hepatitis C (HCV) (2 arms), sponsored by The Kirby Institute. Primary endpoint: Undetectable HCV RNA (SVR12). Started Aug 2017; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03117569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03117569.